trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['trastuzumab deruxtecan', 'destiny,lung02', 'lung', 'astrazeneca', 'daiichi']
 &amp; presented the interim results from the phase ii destiny-lung02 trial of trastuzumab deruxtecan at the 2022 conference. read more: #esmo2022 #esmo #esmo22 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry